Raphael Pharmaceutical Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, | ||||
|---|---|---|---|---|
| Note · 2024 · 2023 | ||||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $19 | $230 | ||
| Other current assets | 3 | 6 | 7 | * |
| Total current assets | 25 | 237 | * | |
| Non-Current assets: | ||||
| Fixed asset, net | 2 | 2 | ||
| Total assets | $27 | $239 | * | |
| Liabilities and stockholders’ equity (deficit) | ||||
| Current liabilities: | ||||
| Other accounts payable and accrued expenses | 4 | 500 | 94 | * |
| Short term loan | 5 | 41 | - | |
| Payable to related party | 228 | 38 | ||
| Total current liabilities | 769 | 132 | * | |
| Stockholders’ equity (deficit): | ||||
| Common stock, $0.01 par value: | ||||
| Authorized: 21,020,560 shares; | ||||
| Issued and outstanding: 18,701,418 and 18,502,918 as of December 31, 2024 and December 31, 2023, respectively | 187 | 185 | ||
| Receivable on account of shares | - | (100 | )* | |
| Additional paid-in capital | 7,960 | 7,392 | ||
| Accumulated deficit | (8,889) | (7,370 | )* | |
| Total stockholders’ equity (deficit) | (742) | 107 | * | |
| Total liabilities and stockholders’ equity | $27 | $239 | ||
| (*) | reclassified. |
The accompanying notes are an integral part of the condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.